TIAA CREF Investment Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-131,881
| Closed | -$2.34M | – | 3049 |
|
|
2018
Q3 | $2.34M | Sell |
131,881
-10,718
| -8% | -$184K | ﹤0.01% | 2047 |
|
|
2018
Q2 | $1.97M | Buy |
+142,599
| New | +$1.69M | ﹤0.01% | 2183 |
|
|
2017
Q2 | – | Sell |
-133,055
| Closed | -$342K | – | 3219 |
|
|
2017
Q1 | $342K | Sell |
133,055
-4,503
| -3% | -$10.4K | ﹤0.01% | 2900 |
|
|
2016
Q4 | $351K | Sell |
137,558
-3,010
| -2% | -$8.64K | ﹤0.01% | 2940 |
|
|
2016
Q3 | $434 | Hold |
140,568
| – | – | ﹤0.01% | 2909 |
|
|
2016
Q2 | $451K | Buy |
140,568
+3,507
| +3% | +$12.9K | ﹤0.01% | 2903 |
|
|
2016
Q1 | $425K | Hold |
137,061
| – | – | ﹤0.01% | 2832 |
|
|
2015
Q4 | $550K | Sell |
137,061
-46,753
| -25% | -$215K | ﹤0.01% | 2861 |
|
|
2015
Q3 | $842K | Buy |
183,814
+27,541
| +18% | +$144K | ﹤0.01% | 2667 |
|
|
2015
Q2 | $811K | Buy |
156,273
+15,412
| +11% | +$92.4K | ﹤0.01% | 2798 |
|
|
2015
Q1 | $882K | Buy |
140,861
+6,863
| +5% | +$39.6K | ﹤0.01% | 2683 |
|
|
2014
Q4 | $843K | Sell |
133,998
-14,002
| -9% | -$85.3K | ﹤0.01% | 2749 |
|
|
2014
Q3 | $900K | Buy |
148,000
+125
| +0.1% | +$854 | ﹤0.01% | 2694 |
|
|
2014
Q2 | $974K | Buy |
147,875
+30,472
| +26% | +$343K | ﹤0.01% | 2737 |
|
|
2014
Q1 | $2.79M | Sell |
117,403
-4,558
| -4% | -$66.1K | ﹤0.01% | 2029 |
|
|
2013
Q4 | $1.3M | Sell |
121,961
-52,297
| -30% | -$577K | ﹤0.01% | 2509 |
|
|
2013
Q3 | $2.32M | Sell |
174,258
-14,938
| -8% | -$236K | ﹤0.01% | 2110 |
|
|
2013
Q2 | $2.48M | Buy |
+189,196
| New | +$2.55M | ﹤0.01% | 2027 |
|
Other funds holding ECYT
TIAA CREF Investment Management's ECYT Position: Q4 2018 in Review
TIAA CREF Investment Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 131,881 shares — an estimated $2.34M sold.
TIAA CREF Investment Management first reported a position in ECYT in Q2 2013 and held it in 18 quarters. The position peaked at $2.79M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- TIAA CREF Investment Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- TIAA CREF Investment Management sold 131,881 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $2.34M.
- TIAA CREF Investment Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- TIAA CREF Investment Management's Endocyte, Inc. Common Stock position peaked at $2.79M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on TIAA CREF Investment Management's 13F filing for Q4 2018, filed 14 Feb 2019.